Site Search

The top priority in clinical research is protecting the safety of people who participate. Learn more about the numerous layers of review that help keep participants safe.

Dr. John P. Clancy shares new developments in drugs that restore airway surface liquid in the lungs of people with cystic fibrosis, making it easier to clear mucus.

Many people might be put off by the thought of participating in a clinical trial. The increasing life expectancy for CFers like me, however, is a testament to the impact medical research can have on the development of therapies for cystic fibrosis.

Drs. Drucy Borowitz and Manu Jain share new developments in drugs that will treat the underlying cause of cystic fibrosis. 

Historic Time in Treatment of Rare Disease as Promising Drugs Reach Phase 3 Trials

Legislation to Help Speed Research for Cystic Fibrosis and Other Rare Diseases

Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance

Observational study supported by the CF Foundation will monitor real-world experience with Trikafta

Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.

The Cystic Fibrosis Foundation is awarding up to $15.9 million in additional funding to Eloxx Pharmaceuticals Inc. to expand clinical studies of ELX-02, a potential therapy for people with CF who have nonsense mutations.